Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19

NEXT STORY
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
PREV STORY
PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AB Science annonce aujourd’hui que les résultats de l’étude AB12005 du masitinib dans le cancer du pancréas ont été sélectionnés pour être présentés à la prochaine réunion annuelle de l’ASCO.

author_avatar
NASDAQ Market News

Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million

author_avatar
NASDAQ Market News

Pivot Pharmaceuticals Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

BOSTON, MA and VANCOUVER, BC, March 30, 2017 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. ...

author_avatar
NASDAQ Market News